Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1014 participants.

Also called NCT02320721

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,014 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02320721
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Canada, Colombia, France, Germany, Hungary, Italy, Japan, Mexico, Peru, Poland, Romania, South Korea, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02320721. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-05 (actual). Results posted on 2017-07-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Acronym
SENIOR
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin Glargine (HOE901 - U300)
Intervention (Drug)
Insulin Glargine (HOE901 - U100)
Intervention (Drug)
Background therapy
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02320721
Content hash
87539cd63bd872c9c199d1d5c3dd8ab6724f79ba30e6139ddce67ceb703cacbe